Business

Chronic Idiopathic Constipation Market to Witness Comprehensive Growth by 2025

Constipation can be defined as a condition with decreased stool frequency or issues in passing stool. Reduced or tough stool passage is accompanied by hard lumpy stools, incomplete bowel actions, straining, incomplete evacuation, and necessity for manual elimination of stool. Chronic idiopathic constipation (CIC) can be described as an additional, persistent or extreme continuation of the above-mentioned signs and symptoms. Several times, the cause of chronic idiopathic constipation is not known. Since the cause of constipation is uncertain, it is known as idiopathic constipation. Chronic idiopathic constipation Market is often indicated with more than one symptoms.

Based on drug class, the global chronic idiopathic constipation market can be segmented into emollients, laxatives, chloride channel activators, osmotic products, and others. The laxatives segment is likely to expand at a significant pace during the forecast period. The advantage of a laxative is that it can be generally sold over the counter and it can even be prescribed as the first line of treatment to relieve idiopathic constipation.

Request Brochure of Chronic Idiopathic Constipation Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=40697

Based on route of administration, the chronic idiopathic constipation market can be segmented into oral and parenteral. The oral segment is likely to expand at a rapid pace during the forecast period, as patients prefer taking oral drugs as they are convenient, invasive, and require no special training to take drugs. Based on distribution mode, the chronic idiopathic constipation market can be segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment is likely to expand at a significant pace during the forecast period, as patients prefer taking drugs prescribed by the doctor to avoid any possible side-effects. In terms of distribution channel, the chronic idiopathic constipation market can be segmented into hospital pharmacies, retail pharmacies, and online sales.

Key players operating in the global chronic idiopathic constipation market are GlaxoSmithKline Plc., Bayer AG, Allergan Plc., Ironwood Pharmaceuticals, Inc., Astellas Pharma, Inc., Synergy Pharmaceuticals, Inc., Sanofi S.A., and Pfizer, Inc. among others.

Leave a Reply

Your email address will not be published. Required fields are marked *